OTCMKTS:LTUS Lotus Pharmaceuticals (LTUS) Stock Price, News & Analysis $0.0036 0.00 (0.00%) As of 05/15/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Lotus Pharmaceuticals Stock (OTCMKTS:LTUS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lotus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0036▼$0.003650-Day Range N/A52-Week Range$0.0025▼$0.0111VolumeN/AAverage Volume3 shsMarket Capitalization$9.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Lotus Pharmaceuticals, trading under the symbol LTUS on the OTC Market, is a Taiwan-based pharmaceutical company specializing in the research, development, manufacturing and marketing of prescription medications. The company’s core operations encompass both the production of a broad range of generic drugs and the advancement of novel compounds aimed at therapeutic areas such as oncology, central nervous system disorders, cardiovascular diseases and anti-infective treatments. Lotus Pharmaceuticals offers multiple dosage forms, including tablets, capsules, injectables and sterile preparations, to meet the needs of hospital and retail pharmacy channels. The company maintains an active internal R&D program, collaborating with external research organizations and academic institutions to move new molecular entities from preclinical stages into clinical trials while continuously expanding its generic portfolio. Headquartered in Tainan, Taiwan, Lotus Pharmaceuticals serves the domestic healthcare market and exports its products to key territories across Asia. By upholding international quality standards and pursuing strategic partnerships, the company aims to strengthen its geographic reach and enhance its pipeline of innovative and cost-effective therapeutic solutions.AI Generated. May Contain Errors. Read More Receive LTUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lotus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LTUS Stock News HeadlinesLotus Pharmaceuticals Inc.March 31, 2026 | barrons.comBoryung Acquires Taxotere Global Business to Expand into 19 CountriesOctober 29, 2025 | msn.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 19 at 1:00 AM | Banyan Hill Publishing (Ad)Avalo Therapeutics completes enrollment in Phase 2 LOTUS trialOctober 29, 2025 | msn.comAlvogen Announces Sale to Lotus, Creating a Leading International Specialized Generics PlatformSeptember 23, 2025 | finance.yahoo.comAcadia Pharmaceuticals publishes interim LOTUS study data in journalSeptember 12, 2025 | msn.comReal World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental ...September 12, 2025 | finance.yahoo.comPTT to sell stake in Taiwan pharmaceuticals firmJuly 25, 2025 | msn.comSee More Headlines LTUS Stock Analysis - Frequently Asked Questions How have LTUS shares performed this year? Lotus Pharmaceuticals' stock was trading at $0.0030 at the beginning of the year. Since then, LTUS shares have increased by 20.0% and is now trading at $0.0036. How do I buy shares of Lotus Pharmaceuticals? Shares of LTUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lotus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lotus Pharmaceuticals investors own include Vodafone Group (VOD), TILT (TLLTF), NextEra Energy (NEE), Energy Transfer (ET) and Ameriwest Lithium (AWLID). Company Calendar Today5/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:LTUS CIKN/A Webwww.lotuspharma.com Phone(941) 267-9684Fax86-10-6389-9867Employees230Year Founded1966Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares2,644,520,000Free FloatN/AMarket Cap$9.52 million OptionableNot Optionable Beta-1.69 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (OTCMKTS:LTUS) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lotus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lotus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
